Study: Avastin and Lucentis show the same efficacy for wet AMD

10/3/2010 | Los Angeles Times (tiered subscription model)

A head-to-head study found that injectable cancer drug Avastin and standard eye medicine Lucentis, both developed by Genentech, are equally effective in treating wet age-related macular degeneration. The finding might pave the way for FDA approval of Avastin for the condition.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations